Treatment of cardiovascular and related pathologies

Details Treatment of cardiovascular and related pathologies Treatment of cardiovascular and related pathologies

1999-03-25

2000-03-28

Krass, Frederick

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

514351, 514821, A01N 4340

Patent

active

060432594

ABSTRACT:
Compositions and methods for treatment and prevention of hypertrophy, hypertension, congestive heart failure, ischemic heart disease, ischemia-related conditions, such as ischemia reperfusion injury and cellular dysfunction, are described. The methods are directed to administering pharmaceutical compositions containing at least one compound selected from pyridoxal-5'-phosphate, pyridoxine, pyridoxal, and pyridoxamine.

REFERENCES:
patent: 3206463 (1965-09-01), Baetz
patent: 3910921 (1975-10-01), Esanu
patent: 3987177 (1976-10-01), Giudicelli et al.
patent: 4032534 (1977-06-01), Chodkiewicz
patent: 4036844 (1977-07-01), Thorne et al.
patent: 4053607 (1977-10-01), Thorne et al.
patent: 4137316 (1979-01-01), Esanu
patent: 4167562 (1979-09-01), Evers
patent: 4361570 (1982-11-01), Fici
patent: 4369172 (1983-01-01), Schor et al.
patent: 4374841 (1983-02-01), Descamps et al.
patent: 4515771 (1985-05-01), Fine
patent: 4567179 (1986-01-01), Lombardino
patent: 4581363 (1986-04-01), Esanu
patent: 4605741 (1986-08-01), Zagnoli et al.
patent: 4735950 (1988-04-01), Esanu
patent: 4735956 (1988-04-01), Baldwin et al.
patent: 4837239 (1989-06-01), Benjamin et al.
patent: 4843071 (1989-06-01), Hohenwarter
patent: 4962121 (1990-10-01), Hamberger et al.
patent: 5001115 (1991-03-01), Sloan
patent: 5053396 (1991-10-01), Blass
patent: 5118505 (1992-06-01), Koltringer
patent: 5130324 (1992-07-01), Ulrich et al.
patent: 5132115 (1992-07-01), Wolter et al.
patent: 5210083 (1993-05-01), Pfirrmann
patent: 5213813 (1993-05-01), Kornecki et al.
patent: 5254572 (1993-10-01), Serfontein
patent: 5272165 (1993-12-01), Ulrich et al.
patent: 5278154 (1994-01-01), Lacoste et al.
patent: 5288716 (1994-02-01), Speck
patent: 5326757 (1994-07-01), Demopoulos
patent: 5328453 (1994-07-01), Sibalis
patent: 5372999 (1994-12-01), Schneider et al.
patent: 5385937 (1995-01-01), Stamler et al.
patent: 5420112 (1995-05-01), Lewis et al.
patent: 5441972 (1995-08-01), Ogata et al.
patent: 5504090 (1996-04-01), Neely
patent: 5563126 (1996-10-01), Allen et al.
patent: 5569459 (1996-10-01), Shlyankevich
patent: 5569648 (1996-10-01), Lewis et al.
patent: 5631271 (1997-05-01), Serfontein
patent: 5633228 (1997-05-01), Lewis et al.
patent: 5648335 (1997-07-01), Lewis et al.
patent: 5728684 (1998-03-01), Cheng et al.
patent: 5733884 (1998-03-01), Barbul et al.
patent: 5733916 (1998-03-01), Neely
patent: 5770215 (1998-06-01), Moshyedi
patent: 5795873 (1998-08-01), Allen
patent: 5804163 (1998-09-01), Gibby et al.
patent: 5804594 (1998-09-01), Murad
patent: 5833998 (1998-11-01), Biedermann et al.
patent: 5834446 (1999-11-01), Dow et al.
patent: 5840685 (1998-11-01), Fujii et al.
patent: 5847008 (1998-12-01), Doebber et al.
patent: 5858017 (1999-01-01), Demopulos et al.
patent: 5859051 (1999-01-01), Adams et al.
patent: 5874420 (1999-02-01), Pelleg
patent: 5874443 (1999-02-01), Kiely et al.
patent: 5888514 (1999-03-01), Weisman
Chemical Abstract 124:193847, "Effect of Oral Pyridoxine Hydrochloride Supplementation on Arterial Blood Pressure in Patients with Essential Hypertension", Dec. 1995.
"B Vitamins May Cut Heart Disease Risk", Harvard Health Letter, 1 page (1998).
Barrett, S., "Homocysteine: A Cardiovascular Risk Factor Worth Considering", http://www.quackwatch.com/03HealthPromotion/homocysteine.htm l, 2 pages (.COPYRGT.1997).
Bernstein, A., "Vitamin B.sub.6 in Clinical Neurology", Annals of New York Academy of Sciences, vol. 585, pp. 250-260 (1990).
Berger, A.R. et al., "Dose response, coasting, and differential fiber vulnerability in human toxic neuropathy: A prospective study of pyridoxine neurotoxicity", Neurology, vol. 42, No. 7, pp. 1367-1370 (Jul. 1992).
Bode, W. et al., "Pyridoxal-5'-Phosphate and Pyridoxal Biokinetics in Male Wistar Rats Fed Graded Levels of Vitamin B-6", J. Nutr., vol. 121, No. 11, pp. 1738-1745 (Nov. 1991).
Chasan--Taber, L. et al, "A Prospective Study of Folate and Vitamin B.sub.6 and Risk of Myocardial Infarction in US Physians", Journal of the American College of Nutrition, vol. 15, No. 2, pp. 136-143 (Apr. 1996).
Cho, Y. et al., "In Vivo Evidence for a Vitamin B-6 Requirement in Carnitine Synthesis", J. Nutr., vol. 120, pp. 258-265 (1990).
"Computer Generated Search Reports", 70 pages (May 1999).
Ellis, J. et al., "Prevention of Myocardial Infarction by Vitamin B.sub.6 ", Res. Commun. Molec. Pathol. Pharmacol., vol. 89, No. 2, pp. 208-220 (Aug. 1995).
Harada, K. et al., "Studies on Vitamin B.sub.6. (IV) Behavior of Pyridoxal Acylates in the Body After Parenteral Administration", Vitamins Journal of the Vitamin Society of Japan, vol. 45, No. 2, pp. 69-75 (Feb. 1972).
Hoover, D.M. et al., "Ultrastructural Lesions of Pyridoxine Toxicity in Beagle Dogs", Vet. Pathol., vol. 18, pp. 769-777 (1981).
Kok, F. et al., "Low Vitamin B.sub.6 Status in Patients with Acute Myocardial Infarction", Am. J. Cardiol., vol. 63, pp. 513-516 (Mar. 1, 1989).
Krinke, G. et al., "Pyridoxine Megavitaminosis: An Analysis of the Early Changes Induced with Massive Doses of Vitamin B.sub.6 in Rat Primary Sensory Neurons", J. Neuropathol. Exp. Neurol., vol. 44, No. 7, pp. 117-129 (Mar. 1985).
Lal, K. et al., "Hypotensive action of 5-HT receptor agonists in the vitamin B.sub.6 --deficient hypertensive rat", Eur. J. Pharmacol., vol. 234, Nos. 2/3, pp. 183-189 (Apr. 1993).
Lal, K. et al., "Calcium channels in vitamin B.sub.6 deficiency--induced hypertension", Journal of Hypertension, vol. 11, No. 12, pp. 1357-1362 (Dec. 1993).
Lal, K. et al., "The effect of vitamin B.sub.6 on the systolic blood pressure of rats in various animal models of hypertension", Journal of Hypertension, vol. 14, No. 3, pp. 355-363 (Mar. 1996).
Merrill, Jr. et al. "Diseases associated with defects in vitamin B.sub.6 metabolism or utilization", Ann. Rev. Nutr., vol. 7, pp. 137-156 (1987).
Omenn, G. et al., "Preventing Coronary Heart Disease", Circulation, vol. 97, pp. 421-424 (1998).
Paulose, C. et al., "Sympathetic Stimulation and Hypertension in the Pyridoxine--Deficient Adult Rat", Hypertension, vol. 11, No. 4, pp. 387-391 (Apr. 1988).
Rimm, E. et al., "Folate and Vitamin B.sub.6 From Diet and Supplements in Relation to Risk of Coronary Heart Disease Among Women", JAMA, vol. 279, No. 5, pp. 359-364 (Feb. 4, 1998).
Trezise, D. et al., "P.sub.2 purinoceptor antagonist properties of pyridoxal-5-phosphate", Eur. J. Pharmacol., vol. 259, No. 3, pp. 295-300 (Jul. 11, 1994).
Verhoef, P. et al., "Homocysteine Metabolism and Risk of Myocardial Infarction: Relation with Vitamins b.sub.6, B.sub.12, and Folate", Am. J. Epidemiol., vol. 143, No. 9, pp. 845-859 (May 1, 1996).
Vermaak, W.J.H. et al., "Vitamin B.sub.6 and coronary artery disease. Epidemiological Observations and Case studies", Atherosclerosis, vol. 63, pp. 235-238 (Feb. 1987).
Windebank, A., "Neurotoxicity of Pyridoxine Analogs Is Related to Coenzyme Structure", Neurochemical Pathology, vol. 3, pp. 159-167 (1985).
Zempleni, J. et al., "The utilization of intravenously infused pyridoxine in humans", Clinica Chimica Acta, vol. 229, Nos. 1, 2, pp. 27-36, (Sep. 1994).

Affiliated with

Also associated with

Rating

Treatment of cardiovascular and related pathologies does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment of cardiovascular and related pathologies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of cardiovascular and related pathologies will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1326331